RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors

Cancer Research

Volumn 65, Issue 20, 2005, Pages 9347-9354

  Kim, Wun Jae ^a,d   Kim, Eun Jung ^a   Jeong, Pildu ^a   Quan, Changyi ^a,b   Kim, Jiyeon ^a   Li, Qing Lin ^a   Yang, Jeong Ook ^a   Ito, Yoshiaki ^c   Bae, Suk Chul ^a,d  

^a Chungbuk National University College of Medicine   (South Korea)

^b YANBIAN UNIVERSITY   (China)

^c INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^d Chungbuk National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; BLADDER TUMOR; CANCER CELL CULTURE; CARCINOGENESIS; CONTROLLED STUDY; DNA METHYLATION; FEMALE; GENE; GENE INACTIVATION; GENE SILENCING; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; RISK FACTOR; RUNX3 GENE; STOMACH CANCER; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR SUPPRESSOR GENE;

BASE SEQUENCE; CELL LINE, TUMOR; CORE BINDING FACTOR ALPHA 3 SUBUNIT; DISEASE PROGRESSION; DNA METHYLATION; DNA, NEOPLASM; EXONS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POINT MUTATION; PROGNOSIS; URINARY BLADDER NEOPLASMS;

EID: 27144524894     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-1647     Document Type: Article

References (45)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996;46:5-27.
2. Robertson KD. DNA methylation, methyltransferases, and cancer. Oncogene 2001;20:3139-55.
3. Czerniak B, Herz F, Wersto RP, Koss LG. Asymmetric distribution of oncogene products at mitosis. Proc Natl Acad Sci U S A 1992;89:4860-3.
4. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;329:1318-27.
5. Al Sukhun S, Hussain M. Molecular biology of transitional cell carcinoma. Crit Rev Oncol Hematol 2003;47:181-93.
6. Orntoft TF, Wolf H. Molecular alterations in bladder cancer. Urol Res 1998;26:223-33.
7. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999;21:163-7.
8. Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman JG. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 2001;10:687-92.
9. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000;16:168-74.
10. Ohtani-Fujita N, Dryja TP, Rapaport JM, et al. Hypermethylation in the retinoblastoma gene is associated with unilateral, sporadic retinoblastoma. Cancer Genet Cytogenet 1997;98:43-9.
11. Tada Y, Wada M, Taguchi K, et al. The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Cancer Res 2002;62:4048-53.
12. Chan MW, Chan LW, Tang NL, et al. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res 2002;8:464-70.
13. Dulaimi E, Uzzo RG, Greenberg RE, Al Saleem T, Cairns P. Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin Cancer Res 2004;10:1887-93.
14. Lee MG, Kim HY, Byun DS, et al. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma. Cancer Res 2001;61:6688-92.
15. Maruyama R, Toyooka S, Toyooka KO, et al. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res 2001;61:8659-63.
16. Chan MW, Chan LW, Tang NL, et al. Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients. Int J Cancer 2003;104:611-6.
17. Orlow I, LaRue H, Osman I, et al. Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence. Am J Pathol 1999;155:105-13.
18. Kagoshima H, Shigesada K, Satake M, et al. The Runt domain identifies a new family of heteromeric transcriptional regulators. Trends Genet 1993;9:338-41.
19. Ito Y. Oncogenic potential of the RUNX gene family: 'overview'. Oncogene 2004;23:4198-208.
20. Wang S, Wang Q, Crute BE, Melnikova IN, Keller SR, Speck NA. Cloning and characterization of subunits of the T-cell receptor and murine leukemia virus enhancer core-binding factor. Mol Cell Biol 1993;13:3324-39.
21. Ogawa E, Inuzuka M, Maruyama M, et al. Molecular cloning and characterization of PEBP2 β, the heterodimeric partner of a novel Drosophila runt-related DNA binding protein PEBP2 α. Virology 1993;194:314-31.
22. Bae SC, Choi JK. Tumor suppressor activity of RUNX3. Oncogene 2004;23:4336-40.
23. Blyth K, Cameron ER, Neil JC. The RUNX genes: gain or loss of function in cancer. Nat Rev Cancer 2005;5:376-87.
24. Look AT. Oncogenic transcription factors in the human acute leukemias. Science 1997;278:1059-64.
25. Otto F, Thornell AP, Crompton T, et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 1997;89:765-71.
26. Komori T, Yagi H, Nomura S, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997;89:755-64.
27. Mundlos S, Otto F, Mundlos C, et al. Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell 1997;89:773-9.
28. Lee B, Thirunavukkarasu K, Zhou L, et al. Missense mutations abolishing DNA binding of the osteoblast-specific transcription factor OSF2/CBFA1 in cleidocranial dysplasia. Nat Genet 1997;16:307-10.
29. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997;89:747-54.
30. Bae SC, Takahashi E, Zhang YW, et al. Cloning, mapping and expression of PEBP2 α C, a third gene encoding the mammalian Runt domain. Gene 1995;159: 245-8.
31. Li QL, Ito K, Sakakura C, et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002;109:113-24.
32. Frommer M, McDonald LE, Millar DS, et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci U S A 1992;89:1827-31.
33. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
34. Cameron EE, Baylin SB, Herman JG. p15(INK4B) CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing. Blood 1999;94:2445-51.
35. Massague J. How cells read TGF-β signals. Nat Rev Mol Cell Biol 2000;1:169-78.
36. Derynck R, Gelbart WM, Harland RM, et al. Nomenclature: vertebrate mediators of TGFβ family signals. Cell 1996;87:173.
37. Xiao WH, Liu WW. Hemizygous deletion and hypermethylation of RUNX3 gene in hepatocellular carcinoma. World J Gastroenterol 2004;10:376-80.
38. Kato N, Tamura G, Fukase M, Shibuya H, Motoyama T. Hypermethylation of the RUNX3 gene promoter in testicular yolk sac tumor of infants. Am J Pathol 2003;163:387-91.
39. Tozawa T, Tamura G, Honda T, et al. Promoter hypermethylation of DAP-kinase is associated with poor survival in primary biliary tract carcinoma patients. Cancer Sci 2004;95:736-40.
40. Kang S, Kim JW, Kang GH, et al. Polymorphism in folate- and methionine-metabolizing enzyme and aberrant CpG island hypermethylation in uterine cervical cancer. Gynecol Oncol 2005;96:173-80.
41. Li QL, Kim HR, Kim WJ, et al. Transcriptional silencing of the RUNX3 gene by CpG hypermethylation is associated with lung cancer. Biochem Biophys Res Commun 2004;314:223-8.
42. Kang GH, Lee S, Lee HJ, Hwang KS. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J Pathol 2004;302:233-40.
43. Goel A, Arnold CN, Tassone P, et al. Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancers. Int J Cancer 2004;112:754-9.
44. Song WJ, Sullivan MG, Legare RD, et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 1999;23:166-75.
45. Osato M, Yanagida M, Shigesada K, Ito Y. Point mutations of the RUNX1/AML1 gene in sporadic and familial myeloid leukemias. Int J Hematol 2001;74:245-51.